Navigation Links
Reportlinker Adds Successful Strategies for Drug Repositioning
Date:4/20/2011

NEW YORK, April 20, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Successful Strategies for Drug Repositioning

http://www.reportlinker.com/p0483598/Successful-Strategies-for-Drug-Repositioning.html

Introduction

This report Highlights how drug repositioning can provide a low-risk approach to drug development. The success of the approach is illustrated by a number of case histories, mostly arising from serendipitous observations. The report illustrates systematic approaches to identify suitable opportunities that should lead to better success including those being pursued by specialist companies.

Features and benefits

* Analyze and understand the strategies employed in the most successful examples of drug repositioning.

* Discover the key technologies required to establish potential repositioning opportunities.

* Identify the specialist service providers with expertise in the key technologies required to systematically identify repositioning candidates.

* Discover how through repositioning a company can protect its intellectual property.

* Analyze the potential impact that drug repositioning can have on both large pharma companies and small specialist companies.

Highlights

The pharma industry's revenue growth is low and it is failing to introduce sufficient new drugs to offset the impact of patent expirations despite record R&D costs. Repurposing of drugs offers a lower risk, lower cost, approach to new product development. Repurposing of development failures can recover what would otherwise be lost R&D expenditure.

The potential commercial benefits from successful repositioning of a drug are likely to be greater than those offered by simple reformulation, and offers opportunities for extended periods of market exclusivity via the granting of additional patents.

Major companies are well positioned to benefit from the successful repurposing of drugs, especially when they utilize both internal resources and external resources. The effective application of repurposing technologies should enable major companies to significantly enhance their development pipelines.

Your key questions answered

* What are the current advantages of repositioning over other lower risk approaches to drug development?

* What are the key technologies being used to identify new targets for molecules in companies' databases?

* How does drug repositioning improve the intellectual property position of companies that employ this strategy?

* What skills and platforms do specialist companies engaged in drug repositioning possess?

* How have molecules such as sildenafil and thalidomide been repositioned successfully?

TABLE OF CONTENTS

Executive Summary

Chapter 1 Introduction

Chapter 2 Lower Risk Strategies

Chapter 3 What is Repositioning?

Chapter 4 Strategic Approaches to Repositioning

Chapter 5 Successful case studies

Chapter 6 Current Efforts

Chapter 7 Specialist Companies

Chapter 8 Outlook

About the author

Disclaimer

Introduction

Summary

Introduction

The decline in approvals of novel chemical entities

The costs, and risks, of drug development

Lower Risk Strategies

Summary

Introduction

Enantiomeric switches

Active metabolites

Reformulation

Repositioning

What is Repositioning?

Summary

Overview

Commercial implications

Intellectual property issues

Design or serendipity?

Strategic Approaches to Repositioning

Summary

Introduction

Chemical space

New indications

Phenotypic approaches

Informatics-based approaches

Reformulation

Exploiting intellectual property

Increased licensing opportunities

Successful case studies

Summary

Introduction

Bupropion

Minoxidil

Thalidomide

Bosentan

sildenafil (Viagra and Revatio)

Current Efforts

Summary

Introduction

Major opportunities

Rare diseases

Drugs in advanced development

Inhaled formulations

Biological products

Modified formulations

Repurposing by combination

Other approaches

Specialist Companies

Summary

Introduction

Almac Group

Ampio Pharmaceuticals

Anaxomics Biotech

APT Pharmaceuticals

Aureus Sciences

Biovista

Celentyx

Cypress Bioscience

Essentialis

Horizon Discovery

Jenken Biosciences

Melior Discovery

NeuroHealing Pharmaceuticals

Numedicus

OphSmart

Optimata

Ore Pharmaceutical Holdings

Radical Therapeutix

SOM Biotech

Somaxon Pharmaceuticals

Sosei Group

SWITCH Biotech

Tangent Reprofiling

Zalicus

Outlook

Summary

Introduction

Impact on major companies

Impact for specialist companies

Overall perspective

Appendix

Glossary/Abbreviations

Bibliography/References

To order this report:

: Successful Strategies for Drug Repositioning

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Middle Eastern Medical Device Market: Facts and Figures2011
2. Reportlinker Adds Levosimendan - Comprehensive patent search
3. Reportlinker Adds Zolpidem - Key patent, SPC, and data exclusivity expiry (44 country coverage)
4. Reportlinker Adds North America Dental Devices Market Outlook to 2017
5. Reportlinker Adds ENT Devices Market Outlook in Brazil to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices
6. Reportlinker Adds ENT Devices Market Outlook in United States to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices
7. Reportlinker Adds Companion Diagnostics Partnering Terms and Agreements
8. Reportlinker Adds ENT Devices Market Outlook in China to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices
9. Reportlinker Adds Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017
10. Reportlinker Adds Neurology Devices Market Outlook in United States to 2017 - Neurostimulation Devices, Interventional Neurology and Others
11. Reportlinker Adds Arthritis Therapy Area Pipeline Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
Breaking Medicine News(10 mins):